Reimagining Testosterone for Modern Medicine
One Molecule. Re-engineered Biology. Multiple Clinical Indications.
d3-T Pipeline
We are intentionally focused on maximizing pipeline breath and optionality while minimizing development complexity. This enables efficient expansion across multiple indications leveraging shared androgen biology.
Male Hypogonadism: Established Market. New Differentiation.
Testosterone therapy is widely used in men with hypogonadism, which impacts more than 30 million men in the U.S. In men using T treatment, the aromatization of T can contribute to side effects such as gynecomastia and may be involved in the development of edema and hypertension. A significant subset of patients are using aromatase inhibitors to avoid or manage gynecomastia.
d3-T is engineered to reduce aromatization and is being evaluated for its potential to reduce gynecomastia, an estrogen-mediated side effect.
A Large, Underserved Market
Testosterone plays an important role in women’s health. T is a critical hormone in women that naturally declines with age and menopause.
There is currently no FDA-approved testosterone product for women, despite clear demand and widespread off-label use—largely due to safety concerns related to the aromatization of T and its potential link with breast cancer risk.
d3-T is being investigated to explore if a non-aromatizing T could enable a new therapeutic approach in women’s health.
The GLP-1 Era Created a New Problem: Lean Mass Loss
GLP-1 therapies are transforming metabolic medicine, but rapid weight loss comes at a cost. Up to 25-30% of total weight loss is lean mass, including skeletal muscle. Loss of muscle mass compromises strength, metabolic rate and long-term outcomes.
Testosterone is a proven anabolic pathway for preserving muscle and strength, yet the limitations of ordinary T complicate expansion to this population. Unfortunately, the agents currently being studied for muscle loss (including SARMS, myostatin inhibitors) carry the potential for liver toxicity or cardiovascular risk.
d3-T is being evaluated as a differentiated approach to preserving muscle.
GLP-1 Associated Low Libido
Changes in libido have been reported in some patients using GLP-1 therapies. This is an emerging consequence of GLP-1 therapy and is particularly relevant in menopausal women, which are a high proportion of GLP-1 users.
d3-T is being explored as a potential androgen-based research pathway in this setting.
ER+ Breast Cancer (Exploratory): When Decoupling from Estrogen Matters
Preclinical evidence suggests that androgen receptor signalling, when decoupled from estrogen production, may offer therapeutic or prophylactic benefit in ER+ breast cancer.
d3-T’s potential for reduced aromatization supports continued investigation in this space.
